2026-05-20T19:10:32Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/68062024-09-27T20:29:28Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Oliva, Gaetano author Nieto Martinez, Francisco Javier author Foglia Manzillo, Valentina author Cappiello, Silvia author Fiorentino, Eleonora author Di Muccio, Trentina author Scalone, Aldo author Moreno, Javier author Chicharro, Carmen author Carrillo, Eugenia author Butaud, Therese author Guegand, Laurie author Martin, Virginie author Cuisinier, Anne-Marie author McGahie, David author Gueguen, Sylvie author Cañavate, Carmen author Gradoni, Luigi author 2014-10-09 Canine leishmaniasis is an important zoonosis caused by uncontrolled infection with Leishmania infantum, where an inappropriate immune response is not only responsible for permitting this intracellular parasite to multiply, but is also responsible for several of the pathological processes seen in this disease. Effective canine vaccines are therefore a highly desirable prevention tool. In this randomised, double-blinded, controlled trial, the efficacy of the LiESP/QA-21 vaccine (CaniLeish, Virbac, France) was assessed by exposing 90 naïve dogs to natural L. infantum infection during 2 consecutive transmission seasons, in two highly endemic areas of the Mediterranean basin. Regular PCR, culture, serological and clinical examinations were performed, and the infection/disease status of the dogs was classified at each examination. The vaccine was well-tolerated, and provided a significant reduction in the risk of progressing to uncontrolled active infection (p = 0.025) or symptomatic disease (p = 0.046), with an efficacy of 68.4% and a protection rate of 92.7%. The probability of becoming PCR positive was similar between groups, but the probability of returning to a PCR negative condition was higher in the vaccinated group (p = 0.04). In conclusion, we confirmed the interest of using this vaccine as part of a comprehensive control program for canine leishmaniasis, and validated the use of a protocol based on regular in-depth assessments over time to assess the efficacy of a canine leishmaniasis vaccine. PLoS Negl Trop Dis. 2014 Oct 9;8(10):e3213 10.1371/journal.pntd.0003213 1935-2735 1935-2735 PLoS neglected tropical diseases 25299614 http://hdl.handle.net/20.500.12105/6806 A randomised, double-blind, controlled efficacy trial of the LiESP/QA-21 vaccine in naïve dogs exposed to two leishmania infantum transmission seasons